Astrel Genome Limited, a active public limited company, was established on 09 February 2005 in Patancheru, Telangana, India. Engaging in alternative & holistic medicine within the manufacturing sector, it holds CIN: U24230TG2005PLC045301. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹15.00 Cr and a paid-up capital of ₹11.00 Cr.
It upholds a compliant status. Its leadership includes Sree Padma Yarlagadda (Managing Director), Medasani Prasanna Lakshmi (Director), Asha Polavarapu (Director). Past directors included Sree Padma Yarlagadda, Prasannaanjaneya Reddy Lebaka, Medasani Prasanna Lakshmi. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No.F26, Flo-Tsiic, Industrial Park Ameenpur, Patancheru, Telangana, 502319.
U24230TG2005PLC045301
045301
09 February 2005
₹15.00 Cr
₹11.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Astrel Genome Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sree Padma Yarlagadda | Managing Director | 20 Jan 2011 | Current |
| Medasani Prasanna Lakshmi | Director | 02 Oct 2018 | Current |
| Asha Polavarapu | Director | 25 Feb 2013 | Current |
| Munisekhar Medasani | Director | 09 Feb 2005 | Current |
| Sanjeev Kumar Sethi | Additional Director | 15 Feb 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 20 Jan 2011 | Past |
| Pramod Abcsdd | Director | 25 Feb 2013 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Director | 20 Jan 2011 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2013 | Past |
| Pramod Abcsdd | Additional Director | 29 Feb 2016 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Astrel Genome Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.72% increase. The company also saw a substantial improvement in profitability, with a 45.99% increase in profit. The company's net worth dipped by a decrease of 5.92%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Astrel Genome had a promoter holding of 83.38% and a public holding of 16.62%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Astrel Genome, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Astrel Genome, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astrel Genome's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Astrel Genome Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.
Progress on Astrel Genome Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.
Sanjeev Kumar Sethi was appointed as a Additional Director was appointed as a Additional Director on 15 Feb 2025 & has been associated with this company since 10 months 29 days . was recorded as a recent event.
The activity Medasani Prasanna Lakshmi was appointed as a Director was appointed as a Director on 02 Oct 2018 & has been associated with this company since 7 years 3 months . was completed.
Progress on Asha Polavarapu was appointed as a Director was appointed as a Director on 25 Feb 2013 & has been associated with this company since 12 years 10 months . was documented.
The activity Sree Padma Yarlagadda was appointed as a Managing Director was appointed as a Managing Director on 20 Jan 2011 & has been associated with this company since 14 years 11 months . was completed.
The CIN of Astrel Genome Limited is U24230TG2005PLC045301.
Astrel Genome Limited is headquartered at Plot No.F26, Flo-Tsiic, Industrial Park Ameenpur, Patancheru, Telangana, 502319.
Astrel Genome Limited was incorporated on 09 February 2005.
The current directors of Astrel Genome Limited are
The primary industry of Astrel Genome Limited is Manufacturing.
Astrel Genome Limited is unlisted.
The authorized capital of Astrel Genome Limited is ₹15.00 Cr, and the paid-up capital is ₹11.00 Cr.
The compliance status of Astrel Genome Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX